Please login to the form below

Not currently logged in
Email:
Password:

New US drug labelling practices

New rules are being put forward in the US that could require pharmaceutical companies to provide more in-depth label information
New rules are being put forward in the US that could require pharmaceutical companies to provide more in-depth label information about the effect of drugs on women who are pregnant or breastfeeding.

The US Food and Drug Administration (FDA) has proposed major revisions to the way in which drug manufacturers label medicinal products. Any changes in labelling practices are being aimed at increasing the amount of information available to healthcare professionals for issuing advice and prescriptions to pregnant women.

"FDA's goal is to help women, their physicians and their pharmacists have better information about the effects of prescription medicines," said Rear Admiral Dr Sandra Kweder, at the FDA Centre for Drug Evaluation and Research.

"This proposal would help make drug labelling a better communication tool and would potentially have a huge impact on public health and well being for women."

On average, expectant women in the US take between three to five prescription drugs during their pregnancy. Some women may need to continue with a course of medication needed for long-term problems, such as asthma or hypertension.

The FDA began exploring ways to improve drug labelling in the 1990s after determining that information included on labels about pregnancy and breastfeeding was insufficient. Stakeholders have said that the current letter category system being used often leads to inaccurate and over simplified details about the effects of medicines on pregnant women.

29th May 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics